AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02585531
Drug: Hypertonic Saline 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours .
Trial: NCT02585531
Drug: Epinephrine and Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours.
Trial: NCT01150474
Drug: Placebo Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Trial: NCT02380066
Drug: Anyu Peibo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00675701
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT00884663
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets and capsules
Trial: NCT02901496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
Trial: NCT01702181
Drug: OPA-15406
RxNorm normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
Trial: NCT01702181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01862120
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Trial: NCT03368963
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03104699
Drug: AGEN2034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 Monoclonal Antibody
Trial: NCT01462435
Drug: Diclofenac Test (lower dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT01462435
Drug: Diclofenac Test (upper dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT01462435
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg Capsules
Trial: NCT01462435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00234936
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05149898
Drug: ZYN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD.
Trial: NCT00612794
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, once weekly
Trial: NCT03033589
Drug: Marcaine 0.25 % Injectable Solution
RxNorm normalized name: Marcaine 0.25 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
Trial: NCT03033589
Drug: Marcaine 0.25 % Injectable Solution
RxNorm normalized name: Marcaine 0.25 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
Trial: NCT02231307
Drug: SUBLIVAC FIX Birch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01676311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Arm (blinded randomization) for Huperzine A Intervention
Trial: NCT03859570
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00572156
Drug: NutropinAq® (Somatropin [rDNA origin])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (Somatropin) 45µg/kg once daily injection
Trial: NCT00572156
Drug: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
Trial: NCT00572156
Drug: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
Trial: NCT00572156
Drug: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
Trial: NCT00195585
Drug: Isovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03716570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04537585
Drug: Vernonia amygdalina
RxNorm normalized name: Vernonia appendiculata leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity).
Trial: NCT01150513
Drug: EC-T
RxNorm normalized name: Spec-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Trial: NCT01150513
Drug: TP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Trial: NCT01314222
Drug: Placebo matching BMS-954561
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01677403
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nebulised 80mg twice daily
Trial: NCT00291733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tabl
Trial: NCT04626765
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/㎡ for D-3 and D-2
Trial: NCT00657917
Drug: Paromomycin +Gentamicin topical cream
RxNorm normalized name: gentamicin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
Trial: NCT00689208
Drug: Placebo Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00574379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily for 14 days
Trial: NCT00386100
Drug: Avandamet 8 mg/ 2000 mg (ttd)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
Trial: NCT00730470
Drug: U3-1287 (AMG888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
Trial: NCT00243815
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03027973
Drug: Placebo (for UPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic UPA 5 mg
Trial: NCT03027973
Drug: Placebo (for TEA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic TEA 500mg
Trial: NCT02100813
Drug: LEO 43204
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02100813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01889303
Drug: concurrent chemoradiotherapy with 5-FU/CF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles.
Trial: NCT02500667
Drug: N91115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BID
Trial: NCT04652739
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
Trial: NCT03138811
Drug: CSJ117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled once daily dose
Trial: NCT03138811
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled once daily dose
Trial: NCT03247036
Drug: IV thrombolytic (t-PA) treatment vs not
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Stroke Protocol
Trial: NCT03597971
Drug: HMPL004-6599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each cohort, 6 subjects will receive HMPL004-6599
Trial: NCT03597971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each cohort, 2 subjects will receive placebo
Trial: NCT04159766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT01155284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
Trial: NCT03042780
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
Trial: NCT00727649
Drug: Psyllium powder
RxNorm normalized name: psyllium Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
Trial: NCT01584570
Drug: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECG monitoring for evaluation of QTc interval
Trial: NCT03279471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
Trial: NCT03767244
Drug: Androgen Deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
Trial: NCT03767244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo oral tablets daily.
Trial: NCT02991261
Drug: SPARC001 type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type I
Trial: NCT02991261
Drug: SPARC001 type II
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type II
Trial: NCT04557163
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-142 will be given as 1 mg per capsule administered orally with water.
Trial: NCT02991261
Drug: Reference001 type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen
Trial: NCT02991261
Drug: Reference001 type II
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone Acetaminophen
Trial: NCT03655002
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04112498
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on Specified days
Trial: NCT02274038
Drug: Baseline 18F-thymidine (FLT) PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
Trial: NCT02274038
Drug: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare.
Trial: NCT02274038
Drug: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
Trial: NCT03007147
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01332513
Drug: Investigational Medicinal Product (MR1)
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
Trial: NCT01332513
Drug: Investigational Medicinal Product (MR2)
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
Trial: NCT01332513
Drug: Investigational Medicinal Product (MR3)
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
Trial: NCT03007147
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03007147
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT01332513
Drug: Investigational Medicinal Product (MR4)
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
Trial: NCT03007147
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01332513
Drug: Investigational Medicinal Product (MR5)
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
Trial: NCT03007147
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT01332513
Drug: Investigational Medicinal Product (IR)
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
Trial: NCT03007147
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03007147
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT03559426
Drug: Antipsychotic Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
Trial: NCT03559426
Drug: Antipsychotic Maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
Trial: NCT04093570
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 film-coated, immediate-release FDC tablets
Trial: NCT03497988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Trial: NCT00760396
Drug: VGX-1027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will
Trial: NCT00213031
Drug: Carraguard (PC-515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02882373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02114775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
Trial: NCT02201511
Drug: 3 mg PF-06412562 MR tablets_Fasted
RxNorm normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
Trial: NCT02201511
Drug: 2 x 15 mg PF-06412562 MR tablets_Fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 15 mg PF-06412562 modified release tablets administered after an overnight fast